M. Kosiborod

First name
Last name
Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., et al. (2017). Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotranspo. Circulation. http://doi.org/10.1161/circulationaha.117.029190
Cavender, M. A., Norhammar, A., Birkeland, K. I., Jorgensen, M. E., Wilding, J. P., Khunti, K., et al. (2018). SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL. J Am Coll Cardiol. http://doi.org/10.1016/j.jacc.2018.01.085
Cherney, D. Z. I., Repetto, E., Wheeler, D. C., Arnold, S. V., MacLachlan, S., Hunt, P. R., et al. (2019). Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus. Am J Nephrol. http://doi.org/10.1159/000504558
Heerspink, H. J. L., Karasik, A., Thuresson, M., Melzer-Cohen, C., Chodick, G., Khunti, K., et al. (2020). Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. http://doi.org/10.1016/s2213-8587(19)30384-5